Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Colon cancer: the 2023 Korean clinical practice guidelines for diagnosis and treatment.
Ryu HS, Kim HJ, Ji WB, Kim BC, Kim JH, Moon SK, Kang SI, Kwak HD, Kim ES, Kim CH, Kim TH, Noh GT, Park BS, Park HM, Bae JM, Bae JH, Seo NE, Song CH, Ahn MS, Eo JS, Yoon YC, Yoon JK, Lee KH, Lee KH, Lee KY, Lee MS, Lee SH, Lee JM, Lee JE, Lee HH, Ihn MH, Jang JH, Jeon SK, Chae KJ, Choi JH, Pyo DH, Ha GW, Han KS, Hong YK, Hong CW, Kwak JM. Ryu HS, et al. Among authors: ahn ms. Ann Coloproctol. 2024 Apr;40(2):89-113. doi: 10.3393/ac.2024.00059.0008. Epub 2024 Apr 30. Ann Coloproctol. 2024. PMID: 38712437 Free PMC article.
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Beom SH, Kim JG, Baik SH, Shin SH, Park I, Park YS, Lee MA, Lee S, Jeon SY, Han SW, Kang MH, Oh J, Kim JS, Kim JY, Ahn MS, Zang DY, Bae BN, Jo HJ, Kim HK, Kim JH, Yoon JA, Kim DH. Beom SH, et al. Among authors: ahn ms. J Cancer Res Clin Oncol. 2023 Mar;149(3):1131-1143. doi: 10.1007/s00432-022-03946-x. Epub 2022 Mar 27. J Cancer Res Clin Oncol. 2023. PMID: 35344080
Clinical application of whole-genome sequencing of solid tumors for precision oncology.
Kim R, Kim S, Oh BB, Yu WS, Kim CW, Hur H, Son SY, Yang MJ, Cho DS, Ha T, Heo S, Jang JY, Yun JS, Kwack KS, Kim JK, Huh J, Lim SG, Han SU, Lee HW, Park JE, Kim CH, Roh J, Koh YW, Lee D, Kim JH, Lee GH, Noh CK, Jung YJ, Park JW, Sheen S, Ahn MS, Choi YW, Kim TH, Kang SY, Choi JH, Baek SY, Lee KM, Il Kim S, Noh SH, Kim SH, Hwang H, Joo E, Lee S, Shin JY, Yun JY, Park J, Yi K, Kwon Y, Lee WC, Park H, Lim J, Yi B, Koo J, Koh JY, Lee S, Lee Y, Lee BR, Connolly-Strong E, Ju YS, Kwon M. Kim R, et al. Among authors: ahn ms. Exp Mol Med. 2024 Aug;56(8):1856-1868. doi: 10.1038/s12276-024-01288-x. Epub 2024 Aug 13. Exp Mol Med. 2024. PMID: 39138315 Free PMC article.
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).
Sim SH, Kim JE, Kim MH, Park YH, Kim JH, Suh KJ, Koh SJ, Park KH, Kang MJ, Ahn MS, Lee KE, Kim HJ, Ahn HK, Kim HJ, Park KU, Byun JH, Park JH, Lee GW, Lee KS, Sohn J, Jung KH, Park IH. Sim SH, et al. Among authors: ahn ms, ahn hk. Breast. 2022 Oct;65:172-178. doi: 10.1016/j.breast.2022.08.002. Epub 2022 Aug 17. Breast. 2022. PMID: 36029565 Free PMC article. Clinical Trial.
207 results